Sevelamer Hydrochloride

Summary

Sevelamer Hydrochloride (CHEMBL1201492) is an approved small molecule; indicated across 9 conditions including chronic kidney disease and kidney disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 9 conditions
• Clinical trials: 17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201492
Name	Sevelamer Hydrochloride
Type	Small molecule
Max phase	4

Also known as: Renagel, Sevelamer hcl, Sevelamer hydrochloride, Tasermity, SEVELAMER HYDROCHLORIDE, SEVELAMER HCL, Sevelamer HCl

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	4	MONDO:0005300	EFO:0003884
kidney disorder	4	MONDO:0005240	EFO:0003086
hyperphosphatemia	4	MONDO:0000328	HP:0002905
renal osteodystrophy	2	MONDO:0006946	EFO:1001152
secondary hyperparathyroidism	2	MONDO:0006964	EFO:1001173

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE2	8
PHASE3	4
PHASE4	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00324571	PHASE4	COMPLETED	Dialysis Clinical Outcomes Revisited (DCOR) Trial
NCT01755078	PHASE4	COMPLETED	Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
NCT03451019	PHASE4	COMPLETED	Different Effects of Non-calcium Phosphate Binders on Serum Calcium
NCT00441545	PHASE3	COMPLETED	Head to Head Study Against Sevelamer Hydrochloride
NCT00844662	PHASE3	TERMINATED	Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
NCT01057407	PHASE3	COMPLETED	A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
NCT01850602	PHASE3	COMPLETED	A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
NCT00324376	PHASE2	COMPLETED	Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing
NCT00436683	PHASE2	COMPLETED	Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia
NCT00440648	PHASE2	COMPLETED	Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
NCT00505037	PHASE2	COMPLETED	A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
NCT00560300	PHASE2	COMPLETED	Regulation of Bone Formation in Renal Osteodystrophy
NCT00704483	PHASE2	COMPLETED	Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
NCT00704678	PHASE2	COMPLETED	Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
NCT00824460	PHASE2	COMPLETED	Study of Phosphate Levels in Patients With Chronic Kidney Disease
NCT00745589	Not specified	COMPLETED	Sevelamer Hydrochloride in Peritoneal Dialysis Patients
NCT01049815	Not specified	COMPLETED	Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).